OBJECTIVE： To observe clinical efficacy of Shenshao capsules in the treatment of unstable angina （UA） of coronary heart disease， and its effects on heart rate， blood pressure， myocardial consumption of oxygen （MCO）， serum levels of hs-CRP and MMP-9. METHODS： 77 UA patients with coronary heart disease selected from our hospital during May 2014-May 2016 were divided into observation group （39 cases） and control group （38 cases） according to random number tablet. Control group received rountine treatment. Observation group was additionally given Shenshao capsule 1.2 g， tid， on the basis of control group. Both groups were treated for 4 weeks. The heart rate， blood pressure， myocardial oxygen consumption， serum levels of hs-CRP and MMP-9 in 2 groups were observed before and after treatment； stopping and reduced rate of nitroglycerin， and therapeutic efficacy of ECG ST segment were compared between 2 groups. RESULTS： There was no statistical significance in heart rate， blood pressure， myocardial oxygen consumption， serum levels of hs-CRP and MMP-9 between 2 groups before treatment （P＞0.05）. After treatment， above indexes of 2 groups were decreased significantly， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. The stopping and reduced rate of nitroglycerin， total response rate  of ECG ST segment were 82.1％， 87.2％ in observation group， which were better than 63.2％，78.9％ in control group， with statistical significance （P＜0.05）. CONCLUSIONS： Shenshao capsules is effective for coronary heart disease UA， and can effectively reduce heart rate， blood pressure， myocardial oxygen consumption， serum levels of hs-CRP and MMP-9.